Our Programs

Pipeline

We are leveraging our deep understanding of recent biological discoveries in endocrinology to build our clinical pipeline. Our focus is on advancing the development of novel, potentially first-in-class treatments for orphan endocrine diseases with significant unmet need. Livoletide (AZP-531) is an unacylated ghrelin analogue for the treatment of Prader-Willi syndrome and nevanimibe (ATR-101) is an ACAT1 inhibitor being investigated in two orphan adrenal disease; classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome (CS).

 

Millendo Pipeline